Objective Acute respiratory worsening is defined as the unexpected rapid deterioration of idiopathic pulmonary fibrosis (IPF), and idiopathic acute respiratory worsening is known as an acute exacerbation of IPF. Torque teno virus (TTV) is a circular single-stranded DNA virus whose pathological significance remains unclear. The aim of the present study was to investigate the prevalence and titer of TTV DNA in IPF patients with acute respiratory worsening. Methods The serum TTV DNA titer was measured using real-time PCR in nine IPF patients (two treated with steroids and immunosuppressants; seven treated without steroids or immunosuppressants) who developed acute worsening, including five patients with acute exacerbation. The serum TTV DNA titer was also measured in eight stable IPF cases and four IPF cases of lung cancer. In addition, in order to examine time course changes in the TTV DNA titer, the titer was measured more than once, with an interval of four weeks or longer, in eight patients. Results Among the nine IPF patients with acute worsening, the TTV DNA titer was above 1×10 6 copies/ mL in two subjects without acute exacerbation who had been continuously treated with steroids and immunosuppressants. Meanwhile, the mean TTV DNA titer was 2.4±2.6 (×10 4 copies/mL) in the five patients with acute exacerbation and 3.1±3.4 (×10 4 copies/mL) in the eight patients with stable IPF. Moreover, the TTV DNA titers were increased in all three IPF patients who started treatment with steroids and immunosuppressants. Conclusion Our results suggest that it is unlikely that TTV is directly involved in the onset of acute exacerbation of IPF and that the serum TTV DNA titer potentially reflects the immunosuppressive state of the host due to treatment.
Introduction
Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, fibrotic lung disease with a median survival of approximately three years (1, 2) . The natural history of this disorder is unpredictable, with many patients experiencing periods of relative stability punctuated by episodes of acute respiratory worsening, defined in an ATS/ERS/JRS/ALAT statement as the unexpected rapid deterioration of IPF during a stable or slowly progressive natural course (1) . Acute respiratory worsening may occur secondarily to common conditions, such as pneumonia, pulmonary embolism, pneumothorax and cardiac failure. However, many cases of acute respiraDivision of Pulmonary Medicine, Department of Medicine, Jichi Medical University, Japan and Division of Virology, Department of Infection and Immunity, Jichi Medical University, Japantory worsening are of unknown etiology, despite careful clinical evaluations. Idiopathic acute respiratory worsening is called acute exacerbation of IPF (3, 4) , and Collard et al. reported that cases of acute respiratory worsening can be categorized as definitive acute exacerbation, suspected acute exacerbation or other acute worsening (4) . Recent observations suggest that acute respiratory worsening occurs annually in approximately 5-10% of patients with IPF (1, 3) . Acute exacerbation is defined by the onset of rapid deterioration (within days to one month) in symptoms, the lung function and radiographic findings (1, 3, 5) . However, acute exacerbation of IPF may also represent clinically occult but biologically distinct conditions that go undiagnosed (e.g., viral infection, aspiration) (3). Notably, viral infections, especially those with herpesviruses, have been reported to be associated with IPF and may induce acute deterioration (3, 6, 7) .
We previously detected replicative forms of TT virus DNA in the lung tissue of a viremic patient with IPF, thus indicating a possible association between TT virus infection and IPF (8) . The TT virus is an unenveloped, singlestranded, circular DNA virus with a total genomic length of approximately 3.6-3.9 kilobases that infects human beings worldwide (9) . The International Committee on Taxonomy of Viruses has officially named the TT virus as Torque teno virus (TTV) and classified it into a novel family, Anelloviridae (10) . The link between TTV infection and a given pathophysiology remains unproven, although it has been suggested that the viral load is related to the immune status of the host. Recently, Wootton et al. (11) demonstrated that TTV infection is significantly more common in patients with acute exacerbation than in stable controls, although the virus is present in a similar percentage of acute lung injury controls.
The aim of the present study was to investigate the prevalence and titer of TTV DNA in patients with IPF complicated by acute respiratory worsening.
Materials and Methods

Subjects
In order to elucidate the involvement of TTV in the acute respiratory worsening of IPF, the serum TTV DNA titer was measured using real-time polymerase chain reaction (PCR). Between October 2010 and March 2012, nine patients (five men and four women; average age, 71.4 years) who developed acute respiratory worsening, including five patients with acute exacerbation admitted to the Division of Pulmonary Medicine, Jichi Medical University Hospital were enrolled in this study. All patients fulfilled the standard clinical criteria for the diagnosis of IPF (1) . Patients with connective tissue disease, chronic hypersensitivity pneumonitis or asbestosis were excluded. In the acute respiratory worsening group, which comprised acute exacerbation cases, the serum TTV DNA titer was measured in all nine patients using samples collected just before the start of treatment for acute respiratory worsening, including steroid pulse therapy. The serum TTV DNA titer was also measured in eight stable IPF patients and four IPF patients with lung cancer. In order to examine the time course changes in the TTV DNA titer, the titer was measured more than once, with an interval of four weeks or longer, in eight patients (three treated with steroids and immunosuppressants; three treated with pirfenidone and two without treatment). Informed written consent was obtained from each patient. The protocols of this study were approved by the Committee for Human Subjects at Jichi Medical University Hospital.
Detection and quantitation of TTV DNA
Nucleic acids were extracted from 50 μL of the serum samples using the SMI TEST EX R&D (Medical & Biological Laboratories, Nagoya, Japan) and dissolved in 50 μL of nuclease-free distilled water. The PCR methods (UTR PCR) used for TTV DNA detection have been described previously (12) (13) (14) . UTR PCR was carried out in the presence of Perkin-Elmer AmpliTaq Gold (Roche Molecular Systems, Branchburg, USA) and nested primers according to the previously described method (14) , with slight modifications. TTV DNA was quantitated via real-time detection PCR (UTR PCR), which can be used to detect essentially all TTV genotypes in groups 1-5, using 10 μL of the nucleic acid solution as a template, primers NG473-NG352, a doubly labeled probe [NG369-P: 5'-(Fam)-AGT CAA GGG GCA ATT CGG GCT CGG GA-(Tamra)-3'] and the LightCycler Fast Start DNA Master Hybridization Probes kit (Roche Diagnostics GmbH, Mannheim, Germany). The quantification limit of the system was 3 to 5 copies per test capillary (20 μL of reaction mixture). The intra-and interassay reproducibility was determined by testing 10 independent DNA extractions of two reference TTV-positive sera on five different days; the %CV (coefficient of variance based on the value of the crossing point on the LightCycler) was 0.7 and 1.8, respectively. The overall variation was less than 0.53 log.
Statistical analysis
The results are presented as the mean ± SD. The frequency between groups was compared using the MannWhitney U test or chi-square test.
Results
The patient background factors in each group are shown in Table. There were no significant differences in age, gender, smoking history or the peripheral blood lymphocyte count or levels of serum markers for interstitial pneumonia between the four groups with acute respiratory worsening, including five patients with acute exacerbation, the IPF stable group, the IPF plus lung cancer group and the other idiopathic interstitial pneumonia (IIP) group. The cause of acute respiratory worsening in four cases without acute exacerbation was cardiac failure in one case and pneumonia in IPF: idiopathic pulmonary fibrosis, IIPs: idiopathic interstitial pneumonias, AW: acute worsening, AEx: acute exacerbation, PFD: pirfenidone, LTOT: long-term oxygen therapy, CHF: chronic heart failure, NTM: non-tuberculous mycobacteriosis three cases, while the causative bacteria for pneumonia were Streptococcus pneumoniae, Haemophilus influenzae and nontuberculous mycobacterium, all of which were diagnosed using sputum tests. Steroid and immunosuppressant treatment had already been given in two cases in the acute respiratory worsening group without acute exacerbation. Regarding the clinical course, all patients with acute IPF exacerbation and IPF plus lung cancer died during the follow-up period, whereas only one patient each in the acute respiratory worsening group without acute exacerbation and the IPF stable group died. The percentages of patients whose serum was positive for TTV DNA according to the UTR PCR among the subjects with IPF who developed acute respiratory worsening, those with stable IPF, those with IPF complicated by lung cancer and those with stable non-IPF are shown in Table. TTV UTR PCR showed positivity in all cases. The mean TTV DNA titer on real-time UTR PCR was 2.4±2.6 (×10 4 copies/ mL) among the five patients with acute exacerbation and 3.1±3.4 (×10 4 copies/mL) among the eight patients with stable IPF, with no significant differences between the two groups. Meanwhile, among the nine IPF patients with acute respiratory worsening, the average TTV DNA titer quantitated via real-time UTR PCR was markedly higher in the group without acute exacerbation. The distribution of the TTV DNA titer prior to treatment in each group is shown in Fig. 1 . The TTV DNA titer was above 1×10 6 copies/mL in two patients with acute respiratory worsening who had been continuously treated with steroids and immunosuppressants. The changes in the TTV DNA titer measured using realtime UTR PCR more than once with an interval of four weeks or longer in eight cases are shown in Fig. 2 . The TTV DNA titer increased after treatment in all three IPF patients who started therapy with steroids and immunosuppressants and decreased or remained unchanged in five patients who began treatment with drugs other than steroids or immunosuppressants, including three patients treated with pirfenidone. The TTV DNA titer did not increase after treatment in one other IIP patient who started treatment with steroids and immunosuppressants.
Discussion
In this study, the TTV DNA titers detected using realtime UTR PCR were higher in the patients with IPF showing acute respiratory worsening than in those with stable IPF. However, there were no differences between the IPF patients with acute exacerbation and those with stable IPF. Although the cause of acute exacerbation of IPF currently remains unclear, TTV infection is unlikely to be a direct cause of acute exacerbation of IPF. TTV is widely distributed in human populations throughout the world and produces chronic viremia in around 90% of healthy individuals of all ages (15) . The natural history and pathogenic potential of TTV are currently under intensive investigation. We previously showed that infection with TTV influences the activity and prognosis of IPF (8) . However, the pathophysiology of TTV in the respiratory tract of infected humans has not yet been defined. We also previously reported the potential involvement of TTV in the activity of IPF and complications of lung cancer (16) . Most adults are known to be infected with TTV in childhood, with chronic viremia persisting thereafter.
In the present study, the TTV DNA titers detected using real-time UTR PCR were markedly high in two patients treated with steroids and immunosuppressants, both of whom were hospitalized for acute respiratory worsening due to pneumonia. In terms of the time course changes in the TTV DNA titer, all three patients showed an increase in the titer after starting steroid or immunosuppressant treatment. These results indicate the possibility that compromised immunity due to steroid or immunosuppressive therapy in the host lung increases the serum TTV DNA titer in cases of IPF. Several possible explanations for the findings obtained in the present study should be explored. One explanation is that an impaired or suppressed immune system plays a role in the elevation of TTV viremia in patients with IPF complicated by acute respiratory worsening. The TTV load is negatively related to the percentage of circulating CD3 + and CD4 + T cells and positively related to the percentage of circulating B cells, suggesting that TTV results in to lymphocyte imbalance and immunosuppressive effects (17) . Furthermore, it has been reported that the TTV viral load is inversely correlated with the CD4 + T cell count in patients infected with human immunodeficiency virus type 1 (18) and may reflect the immune status of the immunocompromised host. Therefore, it is likely that an impaired or suppressed immune system is involved in the onset of an elevated TTV viral load in IPF patients with acute respiratory worsening.
We previously detected TTV DNA in frozen lung tissue obtained via thoracoscopy from an IPF patient with TTV DNA in the serum (8) . Recently, Wootton et al. (11) demonstrated that TTV infection is significantly more common in patients with acute exacerbation than in stable controls. In their study, an array analysis and sensitive genome-specific PCR reactions revealed the presence of TTV in the bronchoalveolar lavage (BAL) samples of the patients with acute exacerbation of IPF. However, they found no relationships between serum and BAL positivity. Taken together, it is necessary to further elucidate the relationship between proliferation and/or activation in the lungs and the serum titer in order to clarify the involvement of TTV in the development of acute exacerbation or acute respiratory worsening of IPF.
The limitations of this study include the small number of cases treated at one institute, and it is thus necessary to accumulate similar cases for further examinations. In addition, this study was retrospective, and we believe that it is necessary to divide the subjects into groups with high and normal TTV DNA titers and prospectively follow their clinical course and complications.
Conclusion
The present results suggest that it is unlikely that TTV is directly involved in the acute exacerbation of IPF, whereas the serum TTV DNA titer potentially reflects the immunosuppressive state of the host due to treatment. In this context, future studies of the role of a high TTV viral load in patients with respiratory diseases of unknown etiology are warranted.
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